WO2001028594A3 - Tumor detection by imaging and therapy of tumors - Google Patents

Tumor detection by imaging and therapy of tumors Download PDF

Info

Publication number
WO2001028594A3
WO2001028594A3 PCT/IL2000/000668 IL0000668W WO0128594A3 WO 2001028594 A3 WO2001028594 A3 WO 2001028594A3 IL 0000668 W IL0000668 W IL 0000668W WO 0128594 A3 WO0128594 A3 WO 0128594A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
individual
efficacy
tumorigenic
blood flow
Prior art date
Application number
PCT/IL2000/000668
Other languages
French (fr)
Other versions
WO2001028594A2 (en
Inventor
Ilan Tsarfaty
Miriam Shaharabany
Rinat Abramovitch
Tammar Kushnir
Galia Tsarfaty
Yacov Itzchak
Original Assignee
Fbit Ltd
Ilan Tsarfaty
Miriam Shaharabany
Rinat Abramovitch
Tammar Kushnir
Galia Tsarfaty
Yacov Itzchak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fbit Ltd, Ilan Tsarfaty, Miriam Shaharabany, Rinat Abramovitch, Tammar Kushnir, Galia Tsarfaty, Yacov Itzchak filed Critical Fbit Ltd
Priority to IL14926800A priority Critical patent/IL149268A0/en
Priority to AU79434/00A priority patent/AU7943400A/en
Priority to JP2001531422A priority patent/JP2003512092A/en
Priority to EP00969788A priority patent/EP1221977A2/en
Publication of WO2001028594A2 publication Critical patent/WO2001028594A2/en
Publication of WO2001028594A3 publication Critical patent/WO2001028594A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

A method for detecting or monitoring tumor cells in an individual is provided which is based on routinely used imaging techniques such as magnetic resonance imaging (MRI) and ultrasound techniques. The detection and monitoring of the cells is carried out non-invasively by externally monitoring the level of oxygenation of the cells (measured as BOLD images) and blood flow to the cells (measured by Doppler ultrasound) in a tested tissue of the individual. The method may be used to identify regions in an individual that does not have a pre-known tumorigenic lesion as well as to detect regions having a high probability of comprising cells in a pre-suspected lesion of an individual (which may, for example be a region in where there is a high probability of existence of primary tumor cells based on analysis by routinely used methods). The method comprises use of an agent which administration to the individual or contact with the cells results in enhancement of the oxygen consumption of the cells detectable by the various imaging techniques. The activating agent may, for example, activate the cells by binding to a receptor specifically expressed by the cells. In addition, methods for evaluating the efficacy of anti-tumorigenic treatments based on measuring blood oxygenation levels and blood flow levels to the cells by imaging techniques are also provided. Furthermore, methods for enhancing the efficacy of anti-tumorigenic therapeutic treatments including chemotherapeutical drugs, antibodies, and irradiation treatments are provided which involve administration to the treated individual of an amount of an agent which enhances the oxygenation of the target cells and the blood flow to the target cells in the treated individual. The efficacy of chemical contrast agents used in conjunction with MRI or ultrasound is also enhanced by the provided method.
PCT/IL2000/000668 1999-10-22 2000-10-20 Tumor detection by imaging and therapy of tumors WO2001028594A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IL14926800A IL149268A0 (en) 1999-10-22 2000-10-20 Tumor detection by imaging and therapy of tumors
AU79434/00A AU7943400A (en) 1999-10-22 2000-10-20 Tumor detection by imaging and therapy of tumors
JP2001531422A JP2003512092A (en) 1999-10-22 2000-10-20 Detection and treatment of tumors by diagnostic imaging
EP00969788A EP1221977A2 (en) 1999-10-22 2000-10-20 Tumor detection by imaging and therapy of tumors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL132531 1999-10-22
IL13253199A IL132531A0 (en) 1999-10-22 1999-10-22 Detection and therapy of tumors

Publications (2)

Publication Number Publication Date
WO2001028594A2 WO2001028594A2 (en) 2001-04-26
WO2001028594A3 true WO2001028594A3 (en) 2002-01-10

Family

ID=11073365

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2000/000668 WO2001028594A2 (en) 1999-10-22 2000-10-20 Tumor detection by imaging and therapy of tumors

Country Status (5)

Country Link
EP (1) EP1221977A2 (en)
JP (1) JP2003512092A (en)
AU (1) AU7943400A (en)
IL (1) IL132531A0 (en)
WO (1) WO2001028594A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979999B2 (en) * 2004-02-26 2005-12-27 General Electric Company Method and system of mapping oxygen concentration across a region-of-interest
AT501944B1 (en) * 2005-06-15 2007-06-15 Tissuegnostics Gmbh PROCESS FOR SEGMENTING LEUKOCYTES
JP5242094B2 (en) * 2007-07-17 2013-07-24 株式会社東芝 Medical image photographing apparatus, medical image processing apparatus, and medical image processing program
WO2011155168A1 (en) 2010-06-07 2011-12-15 パナソニック株式会社 Malignant tissue tumor detection method and malignant tissue tumor detection device

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AL-HALLAQ, H. A. ET AL: "MRI measurements correctly predict the relative effects of tumor oxygenating agents on hypoxic fraction in rodent BA1112 tumors", INT. J. RADIAT. ONCOL., BIOL., PHYS. (2000), 47(2), 481-488, XP001015817 *
GALLEZ, BERNARD ET AL: "Pharmacological modifications of the partial pressure of oxygen in murine tumors: evaluation using in vivo EPR oximetry", MAGN. RESON. MED. (1999), 42(4), 627-630, XP002175413 *
JORDAN, B. F. ET AL: "Changes in tumor oxygenation/perfusion induced by the NO donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI", INT. J. RADIAT. ONCOL., BIOL., PHYS. (2000), 48(2), 565-570, XP001015819 *
MURUGANANDHAM, M. (1) ET AL: "Dynamic magnetic resonance imaging in assessment of tumour blood flow and oxygenation.", CURRENT SCIENCE (BANGALORE), (MARCH 25, 1999) VOL. 76, NO. 6, PP. 744-752, XP001015820 *
MURUGANANDHAM, M. ET AL: "Diltiazem enhances tumor blood flow: MRI study in a murine tumor", INT. J. RADIAT. ONCOL., BIOL., PHYS. (1999), 43(2), 413-421, XP001015822 *
TEICHER B.A. ET AL: "Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells.", CANCER RESEARCH, (1981) 41/1 (73-81). CODEN: CNREA8, XP001016302 *

Also Published As

Publication number Publication date
EP1221977A2 (en) 2002-07-17
AU7943400A (en) 2001-04-30
WO2001028594A2 (en) 2001-04-26
JP2003512092A (en) 2003-04-02
IL132531A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
McDannold et al. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits
Ma et al. Applying amide proton transfer‐weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas
McDannold et al. Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption
Welker et al. Thyroid nodules
Kovacs et al. New, simple, ultrasound-guided infiltration of the pudendal nerve: ultrasonographic technique
Beccaria et al. Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits
McDannold et al. MRI‐guided focused ultrasound surgery in the brain: Tests in a primate model
Glickman et al. Electrical impedance scanning: a new approach to skin cancer diagnosis
US20090062645A1 (en) Method for diagnosis and treatment of prostate cancer
Martin et al. Hemostasis of punctured vessels using Doppler-guided high-intensity ultrasound
Albatany et al. Dichloroacetate induced intracellular acidification in glioblastoma: in vivo detection using AACID-CEST MRI at 9.4 Tesla
EP0275284A1 (en) Ultrasound enhancement of transdermal drug delivery
Webber et al. Effectiveness and limitations of reflectance confocal microscopy in detecting persistence of basal cell carcinomas: a preliminary study
Hawighorst et al. Pelvic lesions in patients with treated cervical carcinoma: efficacy of pharmacokinetic analysis of dynamic MR images in distinguishing recurrent tumors from benign conditions.
Pascal et al. Histologic evaluation of activation of acute inflammatory response in a mouse model following ultrasound-mediated blood-brain barrier using different acoustic pressures and microbubble doses
WO1996039933A1 (en) Apparatus and methodology for determining oxygen in biological systems
US10194825B2 (en) Methods and apparatuses for the localization and treatment of disease such as cancer
Delorme et al. Sensitivity of color Doppler sonography: an experimental approach
WO2001028594A3 (en) Tumor detection by imaging and therapy of tumors
Su et al. Histological analysis of human pancreatic carcinoma following irreversible electroporation in a nude mouse model
US7247501B2 (en) Imaging and targeting tumors using sickle cells
US20040254445A1 (en) Use of MRI to screen individuals for prostate cancer
US20130090545A1 (en) Methods and apparatuses for the localization and treatment of cancer
Courivaud et al. Thermal fixation of swine liver tissue after magnetic resonance-guided high-intensity focused ultrasound ablation
WO2003101279A3 (en) Magnetic resonance imaging of metal concentrations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000969788

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2001 531422

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 149268

Country of ref document: IL

Ref document number: 10111096

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000969788

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000969788

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)